AnnaMaria DeSalva is chairman and chief executive officer of Hill+Knowlton Strategies. Previously, she served as senior advisor to the chief executive of DowDuPont, and earlier, as DuPont’s chief communications officer. Prior to DuPont, Ms. DeSalva was vice president of corporate affairs for biopharmaceutical innovation at Pfizer, an advisor to the U.S. Food and Drug Administration, and led the global healthcare practice of Hill & Knowlton. Earlier, at Bristol-Myers Squibb, she led global public affairs for the oncology business and served as director of the Bristol-Myers Squibb Foundation. Ms. DeSalva previously sat on the XPO board of directors, serving first as a director and then as vice chairman prior to the completion of the RXO spin-off. She serves on the board of governors of Argonne National Laboratory of the U.S. Department of Energy and is a member of its compensation and nominating committees. She is a member of The Economic Club of New York, the Partnership for New York City, and the Paley International Council and is a trustee of the Committee for Economic Development of The Conference Board. Additionally, she serves on the boards of the non-profit Project Sunshine and the William & Mary Alumni Association. She is a graduate of The College of William & Mary in Williamsburg, Virginia, where she serves as executive in residence at the Raymond A. Mason School of Business. Ms. DeSalva also completed the Harvard School of Public Health’s Executive Education Program in risk communication, as well as the Advanced Health Leadership Program jointly offered by the University of California, Berkeley and Pompeu University in Spain.